WAIMR has made outstanding progress since its establishment and its expansion into the commercial sector has been extremely successful. Some of our key commercial partnerships include:
One of WAIMR's most important commercial achievements is the creation of a unique spin-off company called Ozgene.
Ozgene has enjoyed rapid growth in recent times and now employs more than 50 staff. It is recognised across the world for its work in providing genetically-modified mice and its clients range from individual researchers, biotechnology companies and research institutes to multinational pharmaceutical companies. It was recently awarded a $12 million contract with the National Institutes of Health in the United States.
For more information visit www.ozgene.com.
BPH Corporate Limited
Biomedical research company BPH Corporate is in partnership with WAIMR and UWA in a bid to commercialise the discovery of the gene HLS5.
HLS5 is a candidate tumour suppressor gene - a gene that allows cancer cells to grow uncontrolled when it is "switched off" or mutated - that could hold the key to developing products that can detect and treat breast, colorectal and prostate cancer. In recognition of its potential in detecting and treating cancer, the HLS5 project headed by WAIMR Director Professor Peter Klinken has attracted over $1 million in research funding.
The market opportunity for HLS5 is substantial as a tumour suppressor gene has a billion dollar market potential.
For more information visit www.bphcorporate.com.au.
Proteomics International Pty Ltd is a natural product biodiscovery company focused on identifying new bioactive peptides and biomarkers from uncharacterized Australian biota, specifically arthropod venoms. Using a proprietary discovery platform incorporating state of the art mass spectrometers and computational bioinformatics algorithms, novel lead candidates with therapeutic potential are identified. The company has established strategic partnerships with key stakeholders in Singapore for discovery purposes.
Established in 2001, Proteomics International offers consultancy and project management expertise across the biological sciences. The company also provides a comprehensive range of contract analytical services including protein identification and sequencing by mass spectrometry, amino acid analysis, 2 dimensional gel electrophoresis, N-terminal sequencing and custom peptide synthesis. The company operates and manages the Proteomics node of the Lotterywest State Biomedical Research Facility and provides management and research expertise for the Diabesity Research Program at the Centre for Food and Genomic Medicine.
Contact Proteomics International for further information and sample processing requirements and costs:
Telephone: +61 8 9389 1992
Dimerix Bioscience Pty Ltd is a privately owned start-up drug discovery company which was established in 2005 as a result of a research project conducted at the Western Australian Institute for Medical Research.
The focus of the company is on G-protein coupled receptors (GPCRs), the single most successful class of drug targets to date.
Dimerix pursues an in-house drug discovery program based on proprietary technologies for the analysis of GPCR function as well as strategic drug development partnerships. The main area of interest is the design of novel drugs which specifically target dimeric and oligomeric GPCR complexes.
This strategy will ultimately lead to more efficacious therapies with fewer side effects.
For more information visit www.dimerix.com.
Professor Grant Morahan launched Geniad, a company which specialises in developing novel genetic screens for testing new drugs and therapies. This genetic based approach is a world-first, with the goal of attracting interest from the pharmaceutical and biotechnology industries.
For more information visit www.geniad.com.